Disease Biomarker Models
Measures of disease severity often evolve slowly over time, and the benefits of intervention may take weeks, months or years to appear. For example, an anti-angiogenic agent may slow the spread of a tumour, a lipid modifier may gradually decrease LDL/cholesterol levels or an Alzheimer's medication could slow the rate of cognitive deterioration. Measuring efficacy is a crucial challenge to the industry, and modelling biomarkers over time can offer a powerful insight into the evolution of a measurement and it's relationship to measures of patient benefit.
The key feature of disease models is that they describe the natural evolution of the baseline disease, and account for the impact of drugs on this process.
At Wright Dose Ltd, we provide a full range of models to characterize your disease biomarkers including:-
- Differential equation models of biomarker cascades
- Time-to-event models for survival or other critical events, including Cox proportional hazards, frailty models and repeated measures time-to-event models.
- Integration of drug effect on key biological parameters
- Optimized trial strategies via simulation
<< PD Categorical